CN Bio
In vitro Non-Alcoholic Steatohepatitis (NASH) Services
FromCN Bio
Our Non-Alcoholic Fatty Liver Disorder (NAFLD)/NASH in vitro Services offer a preclinical tool to test therapeutics in a human-relevant model, replicating key disease phenotypes including fibrosis and reporting clinical biomarkers to allow translatability to clinical trials.
Most popular related searches
non-alcoholic steatohepatitis
liver disorder
clinical trial
biomarker
preclinical trial
fibrosis biomarkers
fibrosis assessment
We offer a collaborative approach, applying our extensive NASH expertise to designing an experiment that best suits your needs. Our established NAFLD/NASH assay can be adapted to investigate specific questions, focus on different endpoints, or provide samples for -omics analysis.
- Explore or validate the effect of your therapeutic in an industry-validated model
- Uses validated cells with known NASH-related genotypes
- Capture clinical markers with proven translatability
- Assess inflammation, fibrosis, steatosis, and cell health biomarkers
- Option to add -omics analysis of samples
- Full project report detailing methods and results and all raw data